Inovio Advances COVID-19 Vaccine to Phase 1 Testing; Analyst Reiterates ‘Buy’

Amid the ongoing public health crisis, Wall Street is eagerly awaiting any piece of good news. Inovio Pharmaceuticals (INO) just came through.On Monday, the vaccine maker, which is up 150% year-to-date, announced that the Investigational New Drug (IND) application for its experimental COVID-19 vaccine, INO-4800, had been accepted by the FDA. Additionally, management revealed that the first patient in the Phase 1 trial had been dosed with the DNA vaccine candidate.Commenting on the development, H.C. Wainwright analyst Raghuram Selvaraju said, “We note that this constitutes a validating milestone for Inovio’s DNA medicine platform—i.e., to rapidly develop and advance a vaccine …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.